Thorough QT trials are often expensive, with an average study costing between $2M and $4M.But, the December 2015 revision to the ICH E14 guidelines has opened the doors to more cost-effective, and less resource intensive solutions to early-phase trials.
Join us in Maidenhead, UK for a half-day workshop on the revised ICH E14 guidelines and the impact the changes have on your early-phase studies.
Participants will interact with industry experts Goran Westerberg, LaCrocina Pharmaceutical Consultants, Raymond Donninger, Covance Clinical Pharmacology Services, and our very own Borje Darpo while they:
- Explore the changes in the regulatory landscape
- Discuss the benefits of Expert Precision QT (EPQT) modelling in a rare disease setting
- Benefit from an overview of Leeds Clinical Research Unit’s data collection capabilities
Unable to attend the workshop?Click here to find out if your study could qualify for a TQT waiver.